Combined PD-1, BRAF and MEK inhibition in BRAFV600E colorectal cancer: a phase 2 trialJun Tian, Ryan B. Corcoran, Marios Giannakis et al.|Nature Medicine|2023Cited by 197
Phase I/II Study of Combined BCL-xL and MEK Inhibition with Navitoclax and Trametinib in KRAS or NRAS Mutant Advanced Solid TumorsRyan B. Corcoran, Geoffrey I. Shapiro, T. Khanh et al.|Clinical Cancer Research|2024Cited by 39